Pacira reports Q1 EPS 65c, consensus 60c

Reports Q1 revenue $168.9M, consensus $175.9M. “We entered 2025 sharply focused on our 5×30 strategy and our transition into an innovative biopharmaceutical organization,” said Frank D. Lee, CEO. “The favorable settlement of our EXPAREL patent litigation marks an early and meaningful milestone in our 5×30 strategy, reinforcing our leadership in musculoskeletal pain and adjacencies for years to come. Our recently established EXPAREL exclusivity runway extends to 2039 and provides long-term visibility that empowers us to confidently execute our 5×30 strategy as we generate significant cash flow. With NOPAIN presenting a significant opportunity to expand our EXPAREL market share and drive growth, we believe we are poised to remain the branded market leader and advance much-needed innovation for the 1 in 4 Americans suffering from chronic pain.”